– 100% response rate in 1L left-sided mCRC (n=8, confirmed and unconfirmed) – 62% response rate in 2L left- and right-sided mCRC (n=13, confirmed and unconfirmed)  UTRECHT, The Netherlands and CAMBRIDGE, Mass., Oct. 24, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics®, Triclonics® and ADClonics®), today announced interim clinical data as of a July 29, 2 ...

- Petosemtamab in combination with FOLFOX /FOLFIRI (1L and 2L mCRC) and as monotherapy (3L+ mCRC), demonstrates antitumor activity and a manageable safety profile UTRECHT, The Netherlands and CAMBRIDGE, Mass., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics®, Triclonics® and ADClonics®), today announced initial interim clinical data as of an Ap ...

Key Takeaways Genmab shares jumped 21.9% in a month on plans to acquire Merus for $8 billion in cash.The acquisition adds petosemtamab, a late-stage oncology candidate, to GMAB's proprietary pipeline.GMAB expects petosemtamab to drive growth, with potential billion-dollar sales contributions by 2029.Shares of Genmab A/S (GMAB) have rallied 21.9% in a month. The stock price rally was observed after the company signed a definitive agreement in late September to acquire Merus N.V. (MRUS) for $97 per share in c ...

Two pundits raised their price targets on the company.Before the market open on the last trading day of the week, two analysts tracking Genmab (GMAB 4.48%) stock felt compelled to raise their price targets on the biotech. This double-barreled blast of bullishness pushed the company's shares more than 4% higher that trading session, easily beating the essentially stagnant S&P 500 (^GSPC 0.01%). The petosemtamab effectNot surprisingly, both lifts were based largely on Genmab's latest acquisition. On Tuesday, ...

Key Points Two prognosticators published updates on the biotech after it announced a major acquisition. It should soon be the owner of fellow European biotech Merus. 10 stocks we like better than Genmab A/s › One day after announcing a sizable acquisition, Denmark-based biotech Genmab (NASDAQ: GMAB) was doing well on the stock exchange Tuesday. A pair of analysts weighed in with bullish new takes on the company, helping push it to a nearly 5% price gain in late-session trading. That figure was many ...

Core Insights - Genmab has agreed to acquire all shares of Merus for $97 per share, totaling $8 billion, enhancing its oncology pipeline [1][4] - The acquisition is supported by both companies' boards and is expected to transition Genmab to a fully owned business model [1][2] - The deal is projected to close in early Q1 2026, with a key asset being Merus' petosemtamab, currently in Phase III development [2][3] Financial Details - The acquisition price represents a 41% premium over Merus' closing stock price on September 26, 2025, and a 44% premium over the 30-day volume-weighted average price of $67.42 [4] - Genmab plans to finance the acquisition through existing cash and $5.5 billion in non-convertible debt, with backing from Morgan Stanley Senior Funding [4] Strategic Implications - The acquisition aligns with Genmab's long-term strategy to become a global biotechnology leader, providing sustainable growth into the next decade [6] - Petosemtamab is expected to be a transformative therapy for head and neck cancer, with potential launch in 2027 depending on clinical outcomes and regulatory approvals [3][6] Advisory Information - Genmab is advised by PJT Partners and Morgan Stanley & Co International, with legal counsel from A&O Shearman and Kromann Reumert [5] - Merus is advised by Jefferies, with legal counsel from Latham & Watkins and NautaDutilh [5]

Core Insights - Genmab A/S is acquiring Merus N.V. for $97 per share in an all-cash transaction valued at approximately $8 billion, aimed at enhancing its oncology portfolio [1][6] - The acquisition includes Merus' late-stage asset, petosemtamab, which is in Phase 3 development, expected to accelerate Genmab's transition to a wholly owned model [3][6] - Following the acquisition, Genmab will have four proprietary programs ready to drive multiple new drug launches, diversifying its revenue streams [4] Financial Metrics - Leerink Partners has set a price target of $34 for GMAB, indicating a potential increase of about 16.61% from its current trading price of $29.33 [2][6] - Genmab's market capitalization is approximately $18.51 billion, with a trading volume of 5.03 million shares on NASDAQ [4] - Merus' stock surged by 38% following the acquisition announcement, reflecting a positive market response [5] Strategic Implications - The acquisition is a significant step for Genmab in expanding its capabilities in cancer treatment and is expected to support sustained growth into the next decade [3][5] - The deal is anticipated to close by early in the first quarter of 2026, aligning with Genmab's strategic goals [3]

Core Viewpoint - Genmab A/S has agreed to acquire Merus N.V. for $97 per share in an all-cash transaction valued at approximately $8 billion, expected to close by early Q1 2026 [1][2]. Group 1: Acquisition Details - The acquisition is aimed at accelerating Genmab's transition to a wholly owned model, expanding and diversifying its revenue streams for sustained growth into the next decade [2]. - The purchase price of $97.00 per share represents a 41% premium over Merus' closing stock price of $68.89 on September 26, 2025, and a 44% premium over its 30-day volume weighted average price of $67.42 [6]. Group 2: Strategic Fit and Pipeline - Adding petosemtamab, Merus' lead asset, aligns with Genmab's expertise in antibody therapy development and commercialization in oncology, enhancing its late-stage pipeline [3][4]. - Following the acquisition, Genmab will have four proprietary programs expected to lead to multiple new drug launches by 2027 [3]. Group 3: Product Potential - Petosemtamab is an EGFRxLGR5 bispecific antibody with potential first- and best-in-class status in head and neck cancer, showing significantly higher overall response rates and median progression-free survival compared to standard care [4]. - Genmab anticipates the initial launch of petosemtamab in 2027, with plans to broaden its development into earlier lines of therapy [5]. Group 4: Financial Projections - Genmab expects petosemtamab to be accretive to EBITDA, with an estimated annual sales potential of at least $1 billion by 2029, and multi-billion-dollar annual revenue potential thereafter [6]. - The deal is viewed positively by analysts, as it adds an asset with peak sales potential of $3 billion to $4 billion in head and neck cancer alone [7][8].

Group 1 - Genmab announced its plan to acquire Merus for approximately $8 billion, significantly boosting Merus's stock price by over 37% [1][3] - Merus is developing petosemtamab, a drug that targets head-and-neck cancer and metastatic colorectal cancer, with potential peak sales estimated between $3 billion to $4 billion for head-and-neck cancer alone [2] - The acquisition is viewed positively as it enhances Genmab's portfolio with late-stage programs that could lead to substantial revenue growth in the 2030s, surpassing previous revenue peaks from Darzalex royalties [2] Group 2 - The deal values Merus at a 41% premium compared to its closing price prior to the announcement, while Genmab's stock experienced a decline of nearly 3% [3] - Analysts have noted that the acquisition is larger than expected, indicating a strategic move by Genmab to strengthen its market position [2][6]

Core Viewpoint - Genmab A/S is in advanced negotiations to acquire Merus NV, a Dutch biotechnology company focused on innovative cancer therapies, which could be announced in the coming days [1][26]. Group 1: Company Overview - Genmab, headquartered in Copenhagen, has a market capitalization of approximately $18.6 billion, while Merus has a market capitalization of about $5.2 billion [4][12]. - If completed, this acquisition would mark Genmab's largest transaction in its history, emphasizing its commitment to strengthening its oncology pipeline [12]. Group 2: Merus and Its Innovations - Merus has attracted interest from several large pharmaceutical companies due to its experimental cancer drug, petosemtamab, which has shown promising clinical trial data in significantly reducing tumors in head and neck cancer patients [9][10]. - The combination of petosemtamab with Merck's Keytruda has demonstrated better efficacy than existing standard therapies, enhancing investor confidence and boosting Merus's stock price [9][10]. Group 3: Strategic Implications - The acquisition of Merus could provide Genmab with a strategic advantage in the competitive immuno-oncology market, expanding its drug portfolio and increasing collaboration opportunities with pharmaceutical giants [12]. - This move reflects a broader trend in the biotechnology sector, where established companies actively seek mergers and acquisitions to acquire breakthrough technologies and promising drug candidates [12].